Daniel J Ranayhossaini et al.
International journal of molecular sciences, 15(10), 17686-17704 (2014-10-02)
Non-small cell lung cancer (NSCLC) affects millions of patients each year worldwide. Existing therapies include epidermal growth factor receptor (EGFR) inhibition using small molecules or antibodies with good efficacy. Unfortunately, intrinsic and acquired resistance to EGFR therapy remains a persistent